Tin tức & Cập nhật

The GOLDEN* programme, a geriatric oncology (GO) programme that has been used in a tertiary cancer centre in Singapore, appeared to effectively carry out its objective of optimizing care in older adults with cancer.

New drug applications approved by US FDA as of 16-30 June 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with pembrolizumab (pembro) in combination with gemcitabine and cisplatin (gem/cis) results in a statistically significant, clinically meaningful improvement in overall survival (OS) when compared with placebo plus gem/cis in patients with previously untreated metastatic or unresectable biliary tract cancer (BTC), results of the KEYNOTE-966 study have shown.

Chemotherapy with pemetrexed and cisplatin with ADI-PEG20 (pegargiminase), an arginine-depleting agent, results in better survival and demonstrates a favourable safety profile in patients with nonepithelioid pleural mesothelioma (PM), according to a study presented at AACR 2023.

For patients with cancer who have recurrent venous thromboembolism (VTE), direct oral anticoagulants (DOACs) compare favourably with low-molecular-weight heparin (LMWH) in terms of recurrence prevention, according to a study.

Implementation of a novel pharmacist-developed, symptom-based, nurse-driven protocol has led to a low failure rate in infusion reaction treatment among infusion-related reactions (IRRs) assessed, results of a study have shown.